Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
Researchers at GM Biosciences Inc. have reported developed a novel CD38xCD3 bispecific IgM T-cell engager IGM-2644 with 10 binding sites for human CD38 (Kd=0.27nM; measured by biolayer interferometry) and one anti-CD3 site (Kd=2.1nM) designed to reduce safety concerns.
Researchers from Beam Therapeutics Inc. presented the discovery and preclinical evaluation of an engineered stem cell antibody paired evasion (ESCAPE) strategy for antibody (Ab)-mediated autologous hematopoietic stem cell (HSC) therapy conditioning for the treatment of hemoglobinopathies.
Researchers from Nordic Nanovector ASA presented the discovery of a novel humanized anti-CD37 monoclonal antibody, NNV-024, engineered to exhibit a strong antibody-dependent cellular cytotoxicity (ADCC).
Multiple myeloma (MM) represents about 10% of all blood cancers, remaining an incurable disease with a 5-year overall survival rate of 56%. B-cell maturation antigen (BCMA) is a receptor in the cell surface that is highly expressed in malignant plasma cells, and in normal cells, that promotes cell proliferation and survival by binding to APRIL and BAFF ligands.
G-protein coupled receptor family C group 5 member D (GPRC5D) is a tumor-associated receptor that is highly expressed in multiple myeloma (MM) and is a potential target for therapy in MM. Preclinical data have been presented for FT-555, an induced pluripotent stem cell (iPSC)-derived CAR-NK (CAR-iNK) cell product that exerts dual targeting on GPRC5D and CD38 in combination with daratumumab.
Peptide-drug conjugates are an emerging class of molecules that allow efficient targeted drug delivery into tumors. Researchers from Oncopeptides AB and their collaborators presented data on the novel peptide-drug conjugate OPDC3, which has a novel alkylating payload, in models of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML).
The most common cause of anemia in chronically ill hospitalized patients is due to inflammatory anemia (IA) that is caused indirectly by diseases such as autoimmune, cancer, chronic kidney disease, congestive heart failure, or pulmonary disease. The precise and common etiology of these diseases involves hypercytokinemia that leads to excessive increases in hepcidin, a master regulator of iron homeostasis that blocks intestinal iron absorption when levels are too persistently high.
Non-Hodgkin lymphomas (NHLs) originate from a clonal expansion of B cells (85%), T cells/NK cells (15%) or macrophages (~1%) due to an accumulation of genetic lesions in tumor suppressor genes. Approximately 82,000 new cases of NHL were diagnosed in 2021.
RSS
